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Abstract 
  
Smooth muscle cell (SMC) differentiation is controlled by a variety of co-factors to activate 
SMC-specific gene expression. We identified the methyltransferase, PRDM6, as a myocardin 
factor binding factor. Interestingly, PRDM6 expression in mouse and humans is highly SMC-
selective. Genome wide association studies (GWAS) identified a locus in the PRDM6 3rd intron 
that is associated with blood pressure (BP) and intracranial aneurysm. Since this locus is also 
associated with differences in PRDM6 expression in human aortic samples, we hypothesize that 
this locus affects the activity of a regulatory element in this region. Based upon several genome 
wide data sets, we identified a region in the PRDM6 3rd intron that drove Luciferase expression 
in a SMC-specific fashion. Furthermore, to identify the regions that regulate PRDM6 expression 
in SMC, we mutated transcription factor binding sequences in a highly conserved region of the 
PRDM6 3rd intron (Int3.1cons) and found that these mutations decrease PRDM6 activity in 
SMC. Through the use of Chromatin immunoprecipitation (ChIP) assays, we identified that the 
Int3.1cons region significantly bound to three known SMC differentiation transcription factors: 
SRF, RBPJ, and TEAD1. We also show preliminary data that suggests that these transcription 
factors interact to coregulate PRDM6 expression. Altogether, this will help us to further 
understand PRDM6 function and effects as they relate to cardiovascular diseases.  
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Background and Significance 
 Differentiated smooth muscle cells (SMC) provide structural support to the vasculature 
and control blood pressure (BP) and blood flow. Defects in the maintenance of SMC 
differentiation contribute to atherosclerosis and hypertension. Since SMCs are defined by the 
expression of the functional genes, known as differentiation markers (i.e. SM myosin heavy 
chain (MHC), SM a-actin, etc.), further identifying the transcriptional regulation of these genes 
will increase our understanding of vascular development and vascular disease. 
 Several factors are known to contribute to the regulation of SMC differentiation. For 
example, serum response factor (SRF) regulates SMC-specific transcription by binding to the 
conserved CArG (CC(A/T)6GG) cis elements in their promoters 1, 2. However, SRF is not a 
smooth muscle specific transcription factor. Yet, the family of Myocardin factors has been 
identified as non-DNA binding regulators of SMC differentiation. Expression of Myocardin is 
not only heart and SMC-specific, but it was also shown to induce SMC differentiation marker 
gene expression in non-SMC, and upon deletion of Myocardin in the mouse model, lethality was 
observed in part due to the lack of SMC differentiation of the dorsal aorta17,18. Furthermore, 
Myocardin physically interacts with the non-specific SRF, forming homodimers, to co-activate 
SMC-specific genes expression 3, 4.   
 Another highly conserved regulatory pathway that drives vascular differentiation is the 
Notch signaling pathway. Notch is a single-pass transmembrane receptor that interacts with the 
Jagged and Delta-like ligand families on adjacent cells, which causes the cleavage of Notch 
intracellular domain (NICD) by g-secretase and the subsequent translocation of NICD to the 
nucleus where it binds to Recombination Signal Binding Protein For Immunoglobulin Kappa J 
(RBPJ), the main DNA binding protein of the Notch signaling pathway in SMC6. Namely, Notch 
MAGIN 
 
4 
signaling has been shown to be necessary for arteriovenous differentiation6. However, the effects 
of Notch signaling are controversial, in regards to the activation or inhibition of SMC 
differentiation gene markers, which could be explained by the effects being in a time-dependent 
fashion. We have previously shown that the transcription factor, RBPJ, represses the expression 
of SMC-specific genes5. Yet notably, NICD binds RBPJ and reverses the RBPJ-dependent 
repression of SM-markers6, and thus can also activate SM-specific gene expression through 
recruitment of MAML5. With the knockout of Notch in mice, arterial vascular SMC-specific 
markers (smoothelin and SM22) decrease as well, providing more evidence of up regulation of 
SM-specific gene expression6. Interestingly, through the analysis of ChIP-seq data, RBPJ 
binding sites are consistently identified within the same open chromatin binding loci as SRF, and 
the Mack lab has shown that these important transcription factors interact to co-regulate gene 
expression essential for proper SMC function5. 
 Chromatin structure is also a major contributor to the regulation of gene expression. 
Histone acetylation and methylation, depending on the amino acid, can lead to open chromatin 
regions that increase the accessibility of genes to transcriptional machinery. DNAse sequencing 
is a technique used to identify regions across the genome that are open chromatin regions by 
enzymatically cleaving the accessible regions of euchromatin. Further, DNAse sequencing not 
only provides data about genes that are accessible, but also open regions that regulate 
transcription of specific genes. The Mack Lab used this DNAse hypersensitivity model to better 
characterize the changes in frequently euchromatic regulatory regions that were SMC-specific, 
when compared to other cell types (see Figure 1). Many labs have shown that histone and DNA 
modifications that regulate chromatin structure also contribute to SMC-specific gene 
expression9,10, although many critical questions remain, especially in regard to the cell-type- and 
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gene-specificity of regulatory pathways and epigenetics, as well as about how chromatin 
modifying enzymes are recruited to the SMC gene promoters. 
 We recently identified the putative methyltransferase, PRDM6, as a myocardin related 
factor-A (MRTF-A) binding partner using a co-IP/mass spec-based approach, and this result was 
confirmed by co-immunoprecipitation and Far Western analysis. Because PRDI-BFI/RIZ domain 
proteins (PRDMs) share homology with the SET (Suvar/Enhancer of zest/Trithorax) family, it is 
thought that PRDMs control cell fate decisions by functioning as histone methyltransferases 
and/or by interacting with positive and negative chromatin remodeling enzymes11. Interestingly, 
PRDM6 expression in mouse and humans is highly SMC-selective 12,13, but the effects of 
PRDM6 on SMC gene expression are highly controversial. We have previously shown that 
siRNA-mediated knockdown of PRDM6 in rat aortic SMC decreased SMC differentiation 
marker gene expression suggesting that PRDM6 and MRTF-A act as co-regulators. However, 
Davis et al have reported that the knockdown of PRDM6 stimulates the expression of Myocardin 
and SMC differentiation markers12. Yet, to further support the importance of PRDM6 in SMC, a 
familial human genetic study described PRDM6 coding mutations that were associated with 
patent ductus arteriosis 14, a syndrome caused by defects in the contraction and remodeling of 
this embryonic vessel. In addition, separate GWAS have identified a locus in PRDM's third 
intron that was associated with BP regulation and intracranial aneurysm15,16. As observed in 
Genotype-Tissue Expression data, this locus was associated to differences in PRDM6 expression 
in human aortae (p=2.3e-5) strongly suggesting that the control of PRDM6 expression is critical 
for normal SMC function. Because this locus is within the PRDM6 third intron we hypothesized 
that it effects PRDM6 expression by altering the activity of a regulatory element in this region. 
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 The goals of my project were to identify the regions of the third intron that regulate 
PRDM6 activity, identify key transcriptional elements that help regulate PRDM6 expression, 
analyze the effects that PRDM6 knockdown had on SM markers and test whether PRDM6 
expression splice variants had an effect on SM markers.   
 
Methods  
Regulatory region cloning- Several regulatory regions within the PRDM6's BP-
associated locus were PCR amplified from human aortic smooth muscle genomic DNA and then 
cloned into the pGL3 basic vector (Promega). These regions include the Int3.1, Int3.2, Int3Plus, 
Int3.1cons, Int3.1cons mutations, and TSS pieces. The Int3.1 region was cloned using a XhoI 
restriction enzyme site to cut the pGL3 vector and insert, before ligating them together.  The 
plasmids were then transformed into bacteria using a heat shock protocol. In brief, the plasmids 
were added to the DH5a competent bugs at a 1:4 ratio and were placed on ice for 10 minutes. 
The tubes were then placed in a 42°C water bath for 1.5 minutes and then placed on ice again for 
2 minutes, followed by 4 volumes of LB media added to the tubes. The tubes were then placed in 
a 37°C shaker for 30 minutes and then plated on agar petri plates. After the plates sat overnight 
in a 37°C incubator, colonies were picked and grown up in 3mL LB media. Following the 
exponential proliferation in LB media, the bacterial bugs were lysed using a Crack-Lysis Buffer 
and the plasmid DNA samples were ran on an agarose electrophoresis gel to confirm that the 
cloned intron piece was successfully inserted into the plasmid. The positive results from the 
crack screen were then prepped with a Mini prep kit and subjected to restriction digest to confirm 
the direction of the inserted piece.   
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 The Int3.2 piece and Int3Plus piece were cloned using the same methods, however they 
were inserted into the pGL3 vector using a PCR infusion cloning reaction.   
Luciferase assay and activity- Human and mouse aortic SMC and mouse endothelial 
cells were seeded in 24-well culture plates. Triplicate wells were transfected with 50 ng of 
promoter-reporter DNA. After 48 hours of incubation at 37°C, luciferase assays were performed 
using the Steady-Glo Luciferase Kit (Promega). Raw luciferase values were normalized to the 
activity of the promoterless pGL3 from parallel experiments.  
Knockdowns and Western Blots- Dharmafect siRNA were designed and then transfected 
into a 6-well plate containing the HuAo smooth muscle cell line. Three of the wells contained the 
siRNA construct, while the other 3 wells were transfected with a control siRNA that targets the 
GFP molecule. After a 48-hour incubation at 37°C, the cells were lysed and scraped for proteins.  
Two PRDM6 knockdowns wells and two control wells were separated and prepped with RNeasy 
kits to isolate the RNA.  Finally, the RNA preps were then used for a cDNA synthesis and 
subsequent reverse transcriptase PCR, where fluorescence was measured based on the amount of 
double-stranded cDNA, and the PRDM6 was compared to the GAPDH control.   
The other PRDM6 knockdown well and control well were used to conduct a BCA assay 
to quantify the amount of protein present in each well. The proteins were then ran using an SDS-
PAGE Western blot, transferred the gel to a membrane, and probed for PRDM6 expression 
levels and SM marker expression using specific primary and rabbit and mouse secondary 
antibodies for the proteins. The film was then developed with multiple exposures to be able to 
indicate levels of SM and PRDM6 proteins present, compared to the GFP target controls.    
Overexpression with Luciferase Assay- Human and mouse aortic SMC were seeded in 
24-well culture plates. Triplicate wells were transfected with 25 ng of promoter-reporter DNA 
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and 25 ng of TF-secondary messenger expression vector. After 48 hours of incubation at 37°C, 
luciferase assays were performed using the Steady-Glo Luciferase Kit (Promega). Raw luciferase 
values were normalized to the activity of the promoterless pGL3 vector + Flag (or Myc) EV from 
parallel experiments. 
Chromatin Immunoprecipitation Assay- HuBrSMC were seeded in 150mm culture 
plates. Once at a confluency of 80-90%, cells were fixed and DNA was cross-linked by adding 
formaldehyde to split media at a final concentration of 0.7% and rocking for 5 minutes at RT. 
Then, 1M Glycine was added, the plates were washed twice with cold 1X PBS and then frozen in 
-80F. Plates were thawed on ice and scraped with 3mL/plate of Cell Lysis Buffer (w/ 1:100 
Phosphatase and Protease inhibitors). Cell lysates were combined from plates and centrifuged at 
2300g for 5 minutes at 4°C, then resuspended in 1X PBS and recentrifuged. The nuclear pellet 
was then completely resuspended in Nuclear Lysis Buffer (250uL/million cells). The lysate was 
then sonicated (9 cycles, 10-2 second pulses/cycle, @80 Amps). The protein concentration was 
obtained by BCA assay and adjusted to 0.8ug/uL. Antibodies were then fixed to magnetic beads 
and the protein was Immunoprecipitated as per Dynabeads (Invitrogen) protocol. The protein and 
bound DNA were then eluted from the beads and the protein was denatured using 4ul of 5M 
NaCl and 2ul of Proteinase K, overnight at 65°C in a water bath. Then, the DNA fragments are 
isolated using the ZYMO ChIP DNA Clean-Up Kit and PCR reactions are conducted using the 
below conditions.  
Total volume=15uL PCR Conditions 
7.5uL- Red Taq 2X Premix 94°C- 1 minute 
4.5uL- dH2O 94°C- 30 seconds 
1uL- 5’ Primer 61°C- 30 seconds 
1uL- 3’ Primer 72°C- 30 seconds 
1uL- ChIP sample 72°C- 4 minutes 
10°C- indefinite 
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Statistics  
Statistical significance was assessed in data using unpaired T-tests or ratio-paired T-tests. 
Statistical significance was determined at a 95% confidence interval, if the p-value<0.05 (*). 
Statistically more significant values were recorded as the p-value<0.005(**), and the p-
value<0.0005(***). Statistics are mentioned in supplemental with the format (T-test type, T, p-
value, df). 
 
Results 
Identifying regulatory regions that drive PRDM6 expression in SMC. We used the following 
criteria to prioritize our examination of potential regulatory regions within the PRDM6 gene: 1) 
DNAse hypersensitivity determinations in human aortic SMC (HuAoSMC) with particular 
attention paid to SMC-selective DHS regions; 2) positioning of regions in relation to expression 
quantitative trait (eQTL) and blood pressure loci that link genetic variations to PRDM6 
expression and diseases; 3) the binding of SRF and RBPJ (known regulators of SMC 
differentiation) as measured by ChIP seq; 4) mammalian sequence conservation in non-coding 
regions which typically associate with regulatory activity, and 5) Chromatin modifications 
associated with active promoter/enhancer elements (H3K4 methylation and H3K27). My overall 
approach was to PCR amplify potentially interesting regions from genomic DNA prepared from 
our HuAoSMC cultures, clone these fragments into the appropriate luciferase vector (into pGL3 
basic vector to assess promoter function or pGL3-SV40 promoter vector to assess enhancer 
function), and then transfect the promoter/enhancer-Luciferase plasmids into various cell types to 
assess cell-type specific activity. 
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Based on our criteria, we focused on the following regions (see Figure 1); Transcription 
start site (TSS) - this region contains the proximal promoter region, exhibits strong DNAse 
hypersensitivity, H3K4 methylation, and H3K27 acetylation, and contains multiple SRF and 
RBPJ binding sites. Intron 3 region 1 (Int3.1) - this region contains strong DHS region that was 
SMC-specific, SRF and RBPJ binding sites, strong H3K4 methylation and H3K27 acetylation, 
and a highly conserved 300 bp region. Intron 3 region 2 (Int3.2) - this region encompasses a 
SMC-specific DHS region and exhibits high levels of H3K4 methylation and H3K27 acetylation. 
Notably, the general region Intron 3 region that we are examining contains many single 
nucleotide polymorphisms (SNPs) in high linkage disequilibrium (LD) that are associated with 
hypertension, intracranial aneurysm, and differences in PRDM6 mRNA levels.  
 
 
 
 
 
 
 
Figure 1. Schematic of the proximal region of the PRDM6 gene that summarizes our DNAse hypersensitivity data, sequence conservation, SRF and RBPJ binding, 
chromatin modifications, location of variants within the BP-associated LD block, and the regulatory regions tested (green lines) (Int3.1cons- red line within Int3.1 
green line). Modified from Bai & Mangum et al. J Clin Invest. 2017 Feb 1;127(2):670-680. 
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As shown in Figure 2A, a 2.4Kb fragment containing the PRDM6 TSS exhibited very 
strong promoter activity in human bronchial (HuBr) SMC (35 fold over empty pGL3 basic 
vector), an activity on par with several of the traditional SMC marker gene promoters.  
Importantly, TSS-luciferase activity in endothelial cells was only 9 fold providing evidence that 
the TSS plays a role in mediating PRDM6’s SMC-specific expression.  
The Int3.1 fragment containing a PRDM6 SMC-specific DHS displayed strong promoter 
activity (6.8 fold) when cloned into the pGL3 basic vector (Figure 2B), and even stronger and 
more SMC-specific activity when cloned upstream of the SV40 promoter (Figure 2C). 
Interestingly, the Int3.2 fragment exhibited little to no activity in the context of the pGL3 basic 
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Figure 2. A) PRDM6 TSS and Int3.1 show activation, while Int3.2 and Int3plus show inhibition. We cloned various regulatory regions into Luciferase promoter 
vectors. Then, we transfected into SMC and non-SMC, then measured Luciferase Activity. B) PRDM6 has site-dependent regulation. We cloned PRDM6 fragments into 
pGL3 vector and transfected into various cell cultures, and measured Luciferase activity to assess promoter-like function.  
C) PRDM6 enhancer function is region-selective. We cloned PRDM6 fragments into pGL3-SV40 vector, and transfected into various cell cultures. We then measured 
Luciferase activity to assess enhancer function of regions.  
A) 
C) B) 
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vector but did act as a weak enhancer when cloned upstream of the SV40 promoter. 
Interestingly, the Int3.2 region inhibited SV40 promoter activity in the non-SMC types strongly 
suggesting that its repressor function is cell-type specific. 
Due to the relative proximity of the Int3.1 and Int3.2 regions, the presence of the eQTLs 
in this region, and the differential effects of these two regions, a major goal of my project was to 
test whether the Int3.1 and Int3.2 regions function coordinately. To test this we cloned a 6Kb 
fragment (Int3Plus) and transfected this construct into mouse HuAoSMC and HuBrSMC. 
Somewhat surprisingly, the Int3Plus region did not drive much luciferase expression in 
HuBrSMC suggesting that the Int3.2 (or perhaps another Int3pluis region) inhibits the positive 
transcriptional activity of the Int3.1 fragment. 
To test whether human variations affect Int3plus activity, our approach was to make 
mutations consistent with eQTL variants (Figure 1) in the Int3plus region and assess for changes 
in transcriptional activity. However, due to the difficulty in cloning the 6Kb Int3plus region we 
began by testing whether other human variations in the Int 3.2 element affect its activity. In brief, 
we PCR amplified the Int3.2 fragment from four different human patient samples and from a 
second cultured cell line of HuSMC, and cloned them into the pGL3 basic and promoter vectors 
to look for differences in transcriptional activity. We identified several variations in this region 
by sequencing, but none showed significant effects on the inhibitory activity of the Int3.2 
fragment.  
 
Cis-Binding Elements Regulate PRDM6 Activity. Since the Int3.1 domain contains a highly 
conserved sequence that bound SRF and RBPJ and that contained potential cis elements for these 
factors (See Figure 1), we hypothesized that this 300 bp region (Int3.1cons) mediated the 
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relatively strong activity of Int3.1 fragment.  Of note, we also identified a TEAD 
(Transcriptional Enhancer Activator Domain) binding site just upstream of the consensus RBPJ 
cis element. TEAD proteins comprise a family of proteins that bind the MCAT cis-acting 
regulatory element7. Specifically, TEAD1 has been shown to negatively correlate to smooth 
muscle-specific gene expression8. Moreover, TEAD1 not only co-regulates SMC genes with 
SRF 8, but we have shown that it also interacts with RBPJ within the same binding regions to 
alter SMC differentiation (Mangum et. al; manuscript under review at Am J Physiol).  
As shown in Figure 2, Int3.1cons had a significantly higher activation across cell types, but most 
notably in HuBrSMC. Piecing together the high levels of SMC-specific activation, mammalian 
conservation, and transcription factor binding motifs, we focused our approach on the function 
and regulation properties of the Int3.1cons region.  
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Figure 3. A) PRDM6 Int3.1cons region has conserved cis-binding motifs. Sequence of PRDM6 Int3.1conserved region (red line in Figure 1) with highlighted 
TEAD1, RBPJ, and SRF binding sites. B) PRDM6 Int3.1cons mutation sequences. The identified mutation sequences of Int3.1cons that were cloned into SV40 and 
transfected to measure change in activity. Mutated base pairs are underlined and capitalized. C) PRDM6 Int3.1cons has increased activation compared to Int3.1. 
We cloned Int3.1 and Int3.1cons into pGL3-SV40 and assessed the luciferase activity in SMC and non-SMC cultures. D) PRDM6 Int3.1cons mutations 
significantly decrease activity. Point mutations were made in Int3.1cons fragment and then cloned into pGL3-SV40 vector. The fragments were then transfected into 
HuBrSMC, and luciferase activity was measured.  
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Utilizing a PCR based approach, we created point mutations in the Int3.1cons fragment to 
test whether these binding sites were important for Int3.1cons activity. Three mutations were 
created at the SRF binding site, RBPJ binding site, and a suspected TEAD1 (MCAT cis-element) 
binding site (Figure 3B). After cloning into the SV40 promoter vector, the mutation fragments all 
had significantly decreased activation from the wild-type fragment in HuBrSMC (Figure 3D). 
Therefore, the conservation of the wild-type transcription factor binding sites must be pivotal for 
the normal enhancer function of the Int3.1cons region, suggesting that these binding sites drive 
the regulation of PRDM6.  
Since the Int3.1cons region had transcription factor binding sequences that when 
mutated, altered activity levels, we used ChIP assays to test whether the region’s binding 
characteristics physically bound to expected transcription factors. ChIP assays use antibodies 
bound to magnetic beads to pull down DNA-bound proteins in fixed cells. Then, by PCR 
amplifying DNA primer specific fragments, we can identify which proteins were bound to 
specific DNA regions. Using HuBrSMC, we discovered that the Int3.1cons region significantly 
binds to SRF, RBPJ, and TEAD1 when compared to normal IgG antibody IP (Figure 4). 
Furthermore, we preliminarily observed that SMAD4 and SMAD2/3 (transcription factors 
activated by TGF-b signaling) were also immunoprecipitated with the Int3.1cons region. The 
TGF-b signaling pathway is the strongest activator for SMC differentiation, and SMAD2/3 has 
been shown to bind to SRF to regulate SM a actin19,20,  suggesting that this enhancer may also be 
regulated by the TGF-b pathway. 
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To further test the involvement of RBPJ/Notch signaling on endogenous PRDM6 
expression, we measured PRDM6 levels by RT qPCR in HuBrSMC treated with siRNA to 
RBPJ. Preliminarily results suggest that PRDM6 levels were considerably decreased in RBPJ-
depleted cells versus cells treated with an siRNA to GFP (Figure 5). 
 
 
 
 
 
 
 
With the knowledge that specific transcription factors are binding to the enhancer region, 
we tested what effects the overexpression of the specific signal pathways had on the activity of 
the Int3.1cons region. In brief, we co-transfected Int3.1cons-luciferase into HuBrSMC with 
along with FLAG/Myc-tagged expression vectors containing either the SRF co-factor, 
Myocardin, the RBPJ co-factor NICD, or TEAD1 (the TEAD factor thought to regulate gene 
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Figure 4. A) PCR band of PRDM6 Int3.1cons shows binding 
to SRF, RBPJ, and TEAD1. SRF, RBPJ, and TEAD1 were 
immunoprecipitated and the bound DNA was then eluted and 
Int3.1cons primers were used to visualize binding levels.  
B) PRDM6 Int3.1cons binds significantly to regulatory 
transcription factors. Quantification of PCR results from 3 
separate ChIP assays shows statistically significant binding 
compared to normal IgG.  
A) B) 
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Figure 5. PRDM6 mRNA Levels decrease after RBPJ 
knockdown. RBPJ was knocked down using siRNA, and 
PRDM6 mRNA levels were quantified using RT-qPCR.  
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expression in SMC). As shown in Figure 6, we observed that Myocardin overexpression caused a 
significant increase in activation of the Int3.1cons providing additional evidence that SRF 
signaling is important for Int3.1cons activity. In contrast, over expression of NICD and TEAD1 
inhibited Int3.1cons, although these results were not statistically significant. Importantly, the 
overexpression of NICD and TEAD1 also decreased the activity of pGL3 basic empty vector 
suggesting that over-expression of these factors may be down-regulating other aspects of 
transcription and/or translation or could be causing cellular toxicity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Since previous results from the Mack lab suggested that RBPJ and TEAD1 work in 
unison, we used an siRNA approach to knockdown TEAD1 in HuBrSMC, and subsequently 
completed a ChIP assay for RBPJ binding levels in comparison to non-targeted control siRNA 
transfected cells. Interestingly, RBPJ binding to the Int3.1cons region decreased drastically when 
TEAD1 expression levels were knocked down, suggesting that TEAD1 expression levels are 
essential for RBPJ binding to Int3.1cons and the regulation of PRDM6 expression in SMC 
(Figure 7). Importantly, we observed no change in total RBPJ expression levels after TEAD1 
knockdown, suggesting that our results were due to changes in binding and not changes in RBPJ 
protein levels. 
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Figure 6. Myocardin overexpression showed 
significant activation of Int3.1cons. Int3.1cons 
was cloned into pGL3 vector and transfected 
with either Myocardin, NICD, or TEAD1 
expression plasmids. Luciferase activity was 
measured and compared to Int3.1cons in pGL3 
with Flag EV or Myc-prk5 EV expression 
plasmids.  
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The Effects of PRDM6 Expression. To test whether PRDM6 regulated SMC-specific gene 
expression we used gain and loss of function approaches in SMC cultures. We first cloned the 
four reported PRDM6 splice variants (see 13 and Figure 8A) into the Flag expression vector and 
over-expressed them in 10T ½ multipotential cells. These cells can be induced to express SMC 
markers under various conditions. We ran a Western Blot and then first probed for PRDM6 
levels using an anti-Flag Ab. The splice variants 3, 4, and 33 were strongly expressed while 
variant 36 was expressed at much lower levels suggesting that the loss of the fourth Zinc finger 
in variant 36 causes the protein to be considerably more unstable (Figures 8B). 
We then stripped the membrane and probed for SM marker gene expression using 
available antibodies to these proteins. We observed little change in SM-marker gene expression, 
although SM MHC and SM22 were slightly down regulated in the variant 36 over-expressing 
cells, reiterating the previous literature, which cites that PRDM6 levels affect sm-marker gene 
expression (Figure 8C). Furthermore, the lower levels of sm-marker genes were most prevalent 
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Figure 7. A) PCR bands of PRDM6 Int3.1cons show decrease of RBPJ binding in TEAD1 knockdown. Using an siRNA-mediated approach, we knocked 
down TEAD1 in HuBrSMC and then conducted a ChIP assay probing for RBPJ and Notch3. B) Quantification of PCR band shows significant decreases in 
RBPJ binding when TEAD1 is knocked down.  We quantified the results seen from PCR, however statistical significance cannot be calculated until further 
experiments are conducted. C) Western Blot confirms TEAD1 knockdown. TEAD1 is shown to knockdown when siRNA treated. RBPJ levels do not 
decrease endogenously from the knockdown of TEAD1. Lamin A/C shows loading control of western blot, and RBPJ levels are consistent from the IP.  
A) B) 
 
C) 
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in the variant 36, which was the lowest expressed PRDM6 variant, which suggests that a certain 
level of stable PRDM6 is needed for normal sm-marker expression.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To test whether PRDM6 was required for SM marker gene expression we attempted to 
deplete PRDM6 expression in HuBrSMC using siRNA. Unfortunately, PRDM6 expression 
levels in control cells were extremely low and we did not observe significant knockdown of 
PRDM6 mRNA in these experiments. Nevertheless, we stripped and probed this blot for SM-
markers, and not surprisingly, there were no obvious alterations of SM MHC or other marker 
levels between the control and the PRDM6 knockdown cells (Figure 9). 
 
 
 
 
Figure 8. A) PRDM6 splice variant structures. PR/SET= methyltransferase domain. Zn= Zinc finger DNA binding site13. 
 B) PRDM6 splice variants were probed using flag antibodies. Constructs were transfected and then Western blotted. C) SM-
marker proteins that were probed using mouse and rabbit antibodies. We transfected PRDM6 splice variants and then ran a 
Western blot. 
  
 
A) 
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Discussion 
Regulation of PRDM6 Transcription. We identified that the 2.4Kb TSS promoter region of 
PRDM6 is highly active in SMC, compared to endothelial cells, which confirms our compiled 
UCSC data that there is specificity to PRDM6 expression. We also identified that the tested 
PRDM6 intronic regions were SM-specific in their activity, regardless of whether the fragment 
activity levels suggested inhibition or activation.  
The high levels of activation of the Int3.1cons, the mutagenic approach to Int3.1cons, and 
the significant ChIP assay binding confirmed our hypothesis that the three known transcription 
factor binding sites within Int3.1cons play an important role in the regulation of PRDM6 
transcription in HuBrSMC. Although, it is still not fully understood in what ways the binding of 
SRF, RBPJ, and TEAD1 directly control expression, we believe that these transcription factors 
are binding to the cis elements of Int3.1cons, and either binding directly to the TSS region and 
driving expression or binding to other transcriptional machinery to control expression of PRDM6 
(Figure 10). This interaction could be due to the close proximity in 3-dimensional space that 
occurs with these regions configured by CTCF and Cohesin proteins that are known to stabilize 
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A) B) 
Figure 9. A) PRDM6-targeted siRNA knockdown shows successful knockdown of PRDM6. I transfected siRNA into cells and then probed for PRDM6 
expression after running a Western blot, and no bands were found on PRDM6 k/d, but there was a small band in the GFP-targeted control. MHC bands below 
showed possible change in levels and tubulin was used as a loading control. B) Quantification of PRDM6-targeted siRNA knockdowns effects on SM markers. 
I transfected into cells and then western blot was probed for sm-marker, which showed only slight variation in levels of SM MHC.  
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theses looping structures of chromatin21. However, further experiments must be conducted to test 
transcription factor interactions, conformational changes and in what ways signaling pathways 
recruit other regulatory elements.  
 
  
We failed to identify human variations that alter the Int3.2 inhibition. By combing LD 
block, GWAS and eQTL data, we will make further combinations of mutations to identify other 
possible human variations that affect the activity of the Int3plus region. This region is a major 
focus due to its inhibition of the Int3.1 region when combined into the Int3plus fragment. This 
could be due to a conformation change in the accessibility of the regions that drive the Int3.1 
activity, or other unidentified binding factors that are somehow inhibiting the activating 
machinery from properly functioning upstream. As seen in Figure 1, the Int3Plus region also 
Figure 10. Dynamics of SRF, RBPJ, and TEAD1 regulated PRDM6 transcription in SMC. SRF, RBPJ, and 
TEAD1 interact with their secondary moieties (Myocardin, NICD, and YAP, respectively) to bind Int3.1cons and 
drive transcription of PRDM6 and affect SMC function and differentiation. 
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includes identified variations that are shown to correlate to altered levels of PRDM6 expression 
in hypertensive patients. Finally, with the conditions adjusted to properly clone this fragment, we 
will follow up by sequencing the Int3plus region and comparing its activity with that of the 
Int3plus region with point mutations that are consistent with the eQTL and GWAS variations to 
see if this repressor-like affect is consistent, or if mutations affect the activity of Int3plus.  
Upon mutating either the TEAD1, SRF, or RBPJ binding motifs in the Int3.1cons region, 
we observed a significant decrease in the activity levels of the Int3.1cons fragment, when there 
was a mutation in either of the three known transcription factor binding sites. This mutagenic 
approach confirmed our hypothesis that the three known transcription factor binding sites within 
Int3.1cons play an important role in the regulation of PRDM6 transcription in HuBrSMC.   
Furthermore, the ChIP assays in HuBrSMC confirmed that SRF, RBPJ, and TEAD1 are, 
in fact, binding significantly to the Int3.1cons region. The significant binding of these 
transcription factors supports our ChIP sequencing data that previously suggested that SRF and 
RBPJ bound to this region (Figure 1). However, the discovery that TEAD1 also binds to 
Int3.1cons, opened another method to regulate PRDM6, as well as arising the question of 
PRDM6 functional involvement in the TGF-b pathway.  
We showed that RBPJ binding to Int3.1cons decreased with the absence of TEAD1, 
suggesting that TEAD1 is necessary for RBPJ binding as well. This finding confirmed our 
hypothesis that was based around evidence that when RBPJ and TEAD1 are found in close 
proximity, they co-regulate activity levels (Mangum et. al; manuscript under review at Am J 
Physiol.). Further, our findings imply that TEAD1 may cause conformational changes to the 
Int3.1cons region to enhance the ability for RBPJ to bind. Moreover, TEAD1 and RBPJ could 
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interact while bound to the DNA to improve stability, and without TEAD1, RBPJ may not be as 
stable while bound to Int3.1cons.  
Interestingly, we also showed that when Myocardin was overexpressed in HuBrSMC 
with the transfected Int3.1cons fragment, the activity of the region significantly increased. The 
significant activation of Int3.1cons, suggests that the activity of Int3.1cons is dependent on 
Myocardin coactivation with SRF, which has been shown to be essential for inducing SMC 
differentiation3,4. With the SRF region within close proximity of the tightly-knit RBPJ and 
TEAD1 binding motifs, we hypothesize that these three transcription factors may cooperate 
and/or compete to regulate transcription levels. Thus the dynamics of SRF, RBPJ and TEAD1 
and their corresponding co-factors, Myocardin, NICD and YAP are likely important for PRDM6 
expression, and we will be following hypotheses that test their interactions and cooperativity.  
When we overexpressed TEAD1, we showed a statistically insignificant decrease in 
Int3.1cons activity. Although these results are consistent with literature that shows that Hippo 
pathway/TEAD1 repress SMC differentiation8, the identification of a significant decrease in 
activity of the Int3.1cons region when we mutated theTEAD1 binding site (MCAT) is not 
consistent with either TEAD1 functioning as a repressor in this context. The possibility of other 
recruited proteins causing the effect on activity levels is a hypothesis that should be explored. By 
expressing the TEAD1 cofactor, YAP, we may be able to more confidently understand the 
effects of TEAD1 binding on PRDM6 levels. However, further experiments must be done to 
understand the downstream effects of TEAD1 binding to Int3.1cons.  
Lastly, we preliminarily showed that when RBPJ is knocked down in HuBrSMC, 
PRDM6 mRNA levels decrease. From this, we can assume that not only is RBPJ significantly 
binding to intronic regulatory regions, but it also directly affects the PRDM6 expression levels. 
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Calculating these values are achieved by normalizing to the GAPDH control levels and the GFP-
targeted knockdown control. Further replicates will need to be conducted to minimize error bars 
and determine statistical significance.  
 
PRDM6 Regulation on SM Differentiation. We also showed that none of the PRDM6 splice 
variants showed a significant effect on SM-markers (Figure 8A). Perhaps other components are 
required to mediate the effects of PRDM6 on SMC-marker gene expression levels. Low 
transfection efficiencies would also make it more difficult to detect changes in our model.  
However, we did preliminarily identify the lower expression level of the variant #36, which may 
suggest that it is an unstable variant of PRDM6. 
The results of my Western analysis for PRDM6 expression indicated that the siRNA 
protocol knocked down PRDM6 in our human SMC cultures. However, we did not notice any 
significant change to SMC marker gene expression that has been seen in previous experiments. 
Further, the lack of mRNA level changes, suggests that our knock down did not actually work. 
However, these mRNA levels had high error rates and replicates would need to be conducted 
with improved efficacy. We are presently evaluating the conditions to better understand how to 
improve the siRNA knockdown of PRDM6. One obstacle is that the endogenous PRDM6 levels 
are low in our cell cultures, and there is not a strong antibody that allows PRDM6 to easily be 
identified on Western blots. The low levels of PRDM6 in our SMC cultures suggests that 
PRDM6 may be important during specific stages of development or differentiation. Moreover, 
PRDM6 could also play a role in the specific structural integrity of the SMC and its extracellular 
space in vivo, however PRDM6 may not be expressed within cell culture plates that do not 
experience the stretch or strain of the human vasculature.  Further, the mRNA levels of PRDM6 
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are often too low to amplify in these PRDM6 knockdown samples. Once the appropriate 
conditions are met, we will be able to further investigate the effects that PRDM6 knockdown has 
on SMC markers.  
 
Future Directions. We are first interested in identifying what the binding factors of PRDM6 are, 
to better understand PRDM6 function. In future experiments, we will be conducting further 
replicates of the transcription factor knockdowns experiment and analyzing PRDM6 mRNA 
levels. To further understand the dynamics of the binding factors to Int3.1cons, we will also be 
replicating the siRNA-mediated TEAD1 knockdowns, as well as knockdowns of SRF and RBPJ 
to analyze how the knockdown of each transcription factor effects the binding of the others to 
Int3.1cons. Moreover, we will continue overexpression of NICD, myocardin, and YAP with 
Int3.1cons mutation plasmids. We hypothesize that the mutated fragments will not be as affected 
by the overexpression. To understand more acutely what drives PRDM6 expression, we will also 
like to perform knockdowns of SRF, TEAD1, and replicates of the RBPJ knockdown to assess 
the effects on PRDM6 mRNA levels. We also are interested in conducting ChIP assays on the 
TSS region and other regions of the upstream PRDM6 introns, with the further goals to 
understand how transcription factors and signaling pathways interact with PRDM6 regulatory 
regions to control PRDM6 expression. Importantly, we will be conducting Chromatin 
Conformation Capture (3C) experiments to test our hypothesis that the intronic regulatory 
regions are directly interacting with the PRDM6 TSS site.   
We would also like to test whether PRDM6 alters histone methylation at the SMC-
specific promoters. We would use Chromatin Immunoprecipitation (ChIP) assays in control and 
PRDM6 knockdown SMC to test the hypothesis that PRDM6 alters H3K4 methylation and/or 
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other positive histone methylation marks at these genes. We would also test how chromatin 
modifications affect sm-marker gene expression.  
Supplemental 
Figure 3. All compared to wt Int3.1cons- CArG mut (unpaired t-test, 3.68, 0.01, 6), MCAT mut 
(unpaired t-test, 2.96, 0.025, 6), RBPJ mut (unpaired t-test, 4.55, 0.004, 6). 
Figure 4. All to normal IgG -SRF (unpaired t-test, 3.59, 0.023, 4), RBPJ (unpaired t-test, 3.90, 
0.018, 4) and TEAD1 (unpaired t-test, 8.82, 0.0009, 4) 
Figure 5. Flag- Myocardin (ratio paired t-test, 4.60, 0.044, 2) 
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